Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Celgene
|
| gptkbp:acquisitionYear |
2018
|
| gptkbp:focus |
oncology
hematology |
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
gptkb:John_Hood
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Impact Biomedicines
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:fedratinib
|
| gptkbp:website |
https://www.impactbiomedicines.com/
|
| gptkbp:bfsParent |
gptkb:fedratinib
|
| gptkbp:bfsLayer |
7
|